FCM
KALA icon

Farallon Capital Management’s KALA BIO KALA Stock Holding History

Farallon Capital Management’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-74
Closed -$3.42M – 97
2017
Q4 		$3.42M Buy
74
+34
+85% +$1.59M 0.03% 76
2017
Q3 		$2.28M Buy
+40
New +$2.19M 0.02% 83

Other funds holding KALA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Farallon Capital Management's KALA Position: Q1 2018 in Review

Farallon Capital Management sold out of KALA BIO (KALA) in Q1 2018, closing a stake of 74 shares — an estimated $3.42M sold.

Farallon Capital Management first reported a position in KALA in Q3 2017 and held it in 2 quarters. The position peaked at $3.42M in Q4 2017. 64 funds tracked by Wall St. Rank hold KALA as of Q1 2018.

  • Farallon Capital Management reported no remaining KALA BIO position as of Q1 2018 after selling out during the quarter.
  • Farallon Capital Management sold 74 KALA BIO shares in Q1 2018, an estimated $3.42M.
  • Farallon Capital Management first reported a position in KALA BIO in Q3 2017 and held it in 2 quarters.
  • Farallon Capital Management's KALA BIO position peaked at $3.42M in Q4 2017.
  • 64 funds tracked by Wall St. Rank held KALA BIO as of Q1 2018.

Based on Farallon Capital Management's 13F filing for Q1 2018, filed 15 May 2018.